Tempest Therapeutics (TPST)’ treatment of familial adenomatous polyposis was granted orphan designation by the FDA, according to a post to the agency’s website.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST:
- Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges
- Tempest Therapeutics price target lowered to $7 from $13 at Scotiabank
- Tempest Therapeutics price target lowered to $16 from $47 at H.C. Wainwright
- Tempest Therapeutics received ‘Study May Proceed’ letter from FDA on TPST-1495
- Tempest Therapeutics granted FTD from FDA for amezalpat